CN107373272B - Soybean isoflavone effervescent tablet and preparation method thereof - Google Patents
Soybean isoflavone effervescent tablet and preparation method thereof Download PDFInfo
- Publication number
- CN107373272B CN107373272B CN201710589036.1A CN201710589036A CN107373272B CN 107373272 B CN107373272 B CN 107373272B CN 201710589036 A CN201710589036 A CN 201710589036A CN 107373272 B CN107373272 B CN 107373272B
- Authority
- CN
- China
- Prior art keywords
- soybean isoflavone
- parts
- vitamin
- effervescent
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 244000068988 Glycine max Species 0.000 title claims abstract description 116
- 235000010469 Glycine max Nutrition 0.000 title claims abstract description 116
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 title claims abstract description 116
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 title claims abstract description 116
- 235000008696 isoflavones Nutrition 0.000 title claims abstract description 116
- 239000007938 effervescent tablet Substances 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 67
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 64
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 56
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 49
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 31
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000011709 vitamin E Substances 0.000 claims abstract description 31
- 229940046009 vitamin E Drugs 0.000 claims abstract description 31
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 31
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 28
- 239000011718 vitamin C Substances 0.000 claims abstract description 28
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 28
- 239000002253 acid Substances 0.000 claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 15
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims description 72
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 48
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 42
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 26
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 claims description 24
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 claims description 24
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 claims description 24
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 claims description 24
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 claims description 24
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 24
- 235000007240 daidzein Nutrition 0.000 claims description 24
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 claims description 24
- 235000006539 genistein Nutrition 0.000 claims description 24
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 24
- 229940045109 genistein Drugs 0.000 claims description 24
- 238000002156 mixing Methods 0.000 claims description 21
- 239000008187 granular material Substances 0.000 claims description 18
- 239000000314 lubricant Substances 0.000 claims description 18
- 239000003513 alkali Substances 0.000 claims description 16
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 14
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 14
- 239000001630 malic acid Substances 0.000 claims description 14
- 235000011090 malic acid Nutrition 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 12
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 12
- 238000007873 sieving Methods 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 239000000262 estrogen Substances 0.000 abstract description 17
- 229940011871 estrogen Drugs 0.000 abstract description 17
- 239000003814 drug Substances 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 7
- 230000003647 oxidation Effects 0.000 abstract description 6
- 238000007254 oxidation reaction Methods 0.000 abstract description 6
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 5
- 230000001502 supplementing effect Effects 0.000 abstract description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 3
- 206010020772 Hypertension Diseases 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 20
- 235000003687 soy isoflavones Nutrition 0.000 description 15
- 235000015165 citric acid Nutrition 0.000 description 12
- 230000036039 immunity Effects 0.000 description 9
- 239000003826 tablet Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 206010027304 Menopausal symptoms Diseases 0.000 description 3
- 206010056344 Menstrual discomfort Diseases 0.000 description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 206010013663 drug dependence Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000003075 phytoestrogen Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 206010046766 uterine cancer Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 2
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000209763 Avena sativa Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010018275 Gingival atrophy Diseases 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 208000024283 Gingival haemorrhages Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000219823 Medicago Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical group [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 201000005562 gingival recession Diseases 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
- A23L2/395—Dry compositions in a particular shape or form
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/40—Effervescence-generating compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/68—Acidifying substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a soybean isoflavone effervescent tablet and a preparation method thereof, which relate to the technical field of health care products and are mainly prepared from the following raw materials in parts by mass: 45-55 parts of soybean isoflavone composition, 3-7 parts of vitamin E, 45-55 parts of vitamin C, 1000 parts of acid agent 900-: (5-200): (1-100): (10-50), the technical problem that most of the existing medicines for supplementing estrogen on the market are artificial estrogen, and have toxic and side effects after long-term administration is solved, and the technical effects that the medicine dependence on human bodies cannot be formed, the effects of resisting oxidation and removing free radicals are strong, and the diseases such as hypertension and hyperlipidemia can be effectively prevented are achieved.
Description
Technical Field
The invention relates to the technical field of health care products, in particular to a soybean isoflavone effervescent tablet and a preparation method thereof.
Background
With the acceleration of life rhythm, the pressure of life of women is getting bigger and worse, and especially women after age 35 have decreased estrogen secretion and decreased immunity, and are more likely to have diseases such as osteoporosis, breast cancer, uterine cancer and the like. Therefore, there is a need to supplement estrogen to women, especially those aged 35 years and older, to improve their physical condition and enhance their immunity, thereby reducing their chances of developing a disease. However, most of the drugs for supplementing estrogen on the market are artificial estrogen, and the drugs have great toxic and side effects even cause drug dependence after being taken for a long time, thereby affecting the health of women.
In view of the above, the present invention is particularly proposed.
Disclosure of Invention
The invention aims to provide a soybean isoflavone effervescent tablet to solve the technical problems that most of the existing medicines for supplementing estrogen on the market are artificial estrogen, and the long-term administration of the medicines can cause great toxic and side effects and even cause medicine dependence to influence the health of women.
The soybean isoflavone effervescent tablet provided by the invention is mainly prepared from the following raw materials in parts by mass: 45-55 parts of soybean isoflavone composition, 3-7 parts of vitamin E, 45-55 parts of vitamin C, 1000 parts of acid agent 900-: (5-200): (1-100): (10-50), preferably (4-6): (9-11): (4-6): (2-4).
Furthermore, the soybean isoflavone effervescent tablet is mainly prepared from the following raw materials in parts by mass: 48-52 parts of soybean isoflavone, 4-6 parts of vitamin E, 48-52 parts of vitamin C, 980 parts of acid agent 940-: (9-11): (4-6): (2-4).
Further, the soybean isoflavone composition is a mixture of daidzin, daidzein, genistein and genistin, and the mass ratio of the daidzin, the daidzein, the genistein and the genistin is 5:10:5:3
Further, the acid agent is selected from at least one of tartaric acid, malic acid, fumaric acid, citric acid or sodium citrate; preferably, the acid agent is a mixture of malic acid and citric acid, and the mass ratio of the two is 1: (5-6).
Further, the alkaline agent is selected from at least one of potassium carbonate, sodium carbonate, calcium carbonate, potassium bicarbonate, sodium bicarbonate and calcium bicarbonate; preferably, the alkaline agent is sodium bicarbonate.
Further, the lubricant is selected from at least one of sodium dodecyl sulfate, magnesium stearate, talcum powder and silicon dioxide; preferably, the lubricant is magnesium stearate.
The invention also aims to provide a preparation method of the soybean isoflavone effervescent tablet, so as to relieve the technical problems that most of the existing medicines for supplementing estrogen on the market are artificial estrogen, and the long-term administration of the medicines can cause great toxic and side effects, even cause medicine dependence and influence the health of women.
The preparation method of the soybean isoflavone effervescent tablet provided by the invention comprises the following steps:
(a) mixing daidzin, daidzein, genistein and genistin uniformly to obtain soybean isoflavone composition;
(b) mixing soybean isoflavone composition, vitamin E, vitamin C, acid agent and alkali agent, and mixing with ethanol to obtain soybean isoflavone effervescent granule;
(c) drying the soybean isoflavone effervescent granules, adding a lubricant, uniformly mixing, and tabletting to obtain the soybean isoflavone effervescent tablets.
Further, the preparation method of the soybean isoflavone effervescent tablet further comprises a step(s), wherein the step(s) is arranged before the step (a) and the step (b), and the step(s) is to pulverize the soybean isoflavone composition, the vitamin E, the vitamin C, the acid agent, the alkali agent and the lubricant and to pass through a 80-mesh sieve.
Further, in the step (c), the temperature for drying is 60 to 70 ℃, preferably 65 ℃.
Further, in the step (b), the prepared soybean isoflavone effervescent granule has a particle size of 14-18 meshes, preferably 16 meshes.
The soybean isoflavone effervescent tablet provided by the invention can supplement female estrogen, improve the immunity of the organism, delay aging, prevent diseases such as osteoporosis, breast cancer, uterine cancer and the like by the synergistic cooperation of the soybean isoflavone composition, the vitamin E, the vitamin C, the acid agent, the alkali agent and the lubricant, has no toxic or side effect on a human body, does not cause drug dependence on the human body, has strong effects of resisting oxidation and removing free radicals, and can effectively prevent diseases such as hypertension, hyperlipidemia and the like.
The preparation method of the soybean isoflavone effervescent tablet provided by the invention has the advantages of simple process, convenience in operation, easiness in large-scale industrial production, reduction in preparation cost and improvement in preparation efficiency.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to examples, but it will be understood by those skilled in the art that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
According to one aspect of the invention, the invention provides a soybean isoflavone effervescent tablet which is mainly prepared from the following raw materials in parts by weight: 45-55 parts of soybean isoflavone composition, 3-7 parts of vitamin E, 45-55 parts of vitamin C, 1000 parts of acid agent 900-: (5-200): (1-100): (10-50), preferably (4-6): (9-11): (4-6): (2-4).
The soybean isoflavone effervescent tablet provided by the invention can supplement female estrogen, improve the immunity of the organism, delay aging and prevent diseases such as osteoporosis, breast cancer, uterine cancer and the like by the synergistic cooperation of the soybean isoflavone composition, the vitamin E, the vitamin C, the acid agent, the alkali agent and the lubricant.
In the present invention, the typical but non-limiting mass fraction of the soy isoflavone composition is, for example, 45.5, 46, 46.5, 47, 47.5, 48, 48.5, 49, 49.5, 50, 50.5, 51, 51.5, 52, 52.5, 53, 53.5, 54 or 54.5.
The soybean isoflavone composition is a mixture of daidzin, daidzein, genistein and genistin, and the daidzin, the daidzein, the genistein and the genistin are all extracted from natural plants, so that the composition has no toxic or side effect on human bodies, does not cause drug dependence on human bodies, can effectively supplement estrogen in female bodies by means of synergistic cooperation of the daidzin, the daidzein, the genistein and the genistin, has strong effects of resisting oxidation and removing free radicals, and can effectively prevent diseases such as hypertension and hyperlipidemia.
Daidzin is a compound extracted from plants, and has effects in scavenging free radicals, inhibiting oxidation of esters in serum, reducing cholesterol and triglyceride content in blood, inhibiting growth of tumor cells, destroying tumor cell structure or inhibiting DNA synthesis, enhancing immunity, inhibiting growth of tumor cells, resisting oxidation, scavenging free radicals, and reducing lipid peroxide.
Daidzein is one of phytoestrogens, is a nonsteroidal compound which is extracted from plants and has estrogen-like function, has the effects of dilating blood vessels, increasing coronary blood flow, reducing blood pressure, slowing down heart rhythm, reducing myocardial oxygen consumption and resisting arrhythmia, has obvious antibacterial effect on staphylococcus aureus and escherichia coli, and can also treat climacteric syndrome and osteoporosis, resist estrogen activity, prevent and treat breast cancer, endometritis and the like.
Genistein is also called phytoestrogen, can be extracted from soybean, clover, alfalfa and oat, has a structure similar to estrogen, can competitively bind with estrogen receptor to play an estrogen-like role, obviously increases the weight of uterus, increases bone density, and simultaneously has the effects of resisting tumor, resisting diabetes and preventing cardiovascular and cerebrovascular diseases.
The genistin is derived from natural plants, has phytoestrogen bidirectional regulation effect, has good effect in inhibiting vascular proliferation, has effects of delaying or preventing malignant tumor from becoming cancer cells in the development process, simultaneously can prevent cholesterol oxidation and hemolysis, can inhibit platelet aggregation, prevent smooth muscle cell proliferation, and can inhibit and assist in treating diseases caused by lipid peroxidation in vivo.
Typical but not limiting parts by mass of vitamin E in the present invention are e.g. 3.2, 3.4, 3.6, 3.8, 4, 4.2, 4.4, 4.6, 4.8, 5, 5.2, 5.4, 5.6, 5.8, 6, 6.2, 6.4, 6.6 or 6.8.
Vitamin E is a fat-soluble vitamin, the hydrolysis product of which is tocopherol, which is one of the most important antioxidants, and the tocopherol can promote the secretion of sex hormones, increase the female estrogen concentration, improve the fertility, inhibit the peroxidation ester reaction in the lens of eyes, expand peripheral blood vessels and improve blood circulation. Vitamin E has a wide role in preventing cardiovascular and cerebrovascular diseases, tumors, diabetes and other complications, central nervous system diseases, motor system diseases, skin diseases and the like.
Typical but not limiting mass fractions of vitamin C are e.g. 45.5, 46, 46.5, 47, 47.5, 48, 48.5, 49, 49.5, 50, 50.5, 51, 51.5, 52, 52.5, 53, 53.5, 54 or 54.5.
Vitamin C is a water-soluble vitamin, and has effects of promoting collagen synthesis, treating scurvy, preventing gingival atrophy and hemorrhage, preventing arteriosclerosis, preventing free radical injury to human body, treating anemia and preventing cancer.
In a preferred embodiment of the present invention, when the soy isoflavone composition is a mixture of daidzin, daidzein, genistein and genistin, and the mass ratio of the daidzin, the daidzein, the genistein and the genistin is 5:10:5:3, the effect of mutual synergy of the daidzin, the daidzein, the genistein and the genistin is better, so that the soy isoflavone has better effects in cancer prevention and treatment, body immunity improvement and aging delay.
In a preferred embodiment of the present invention, the acid agent is at least one selected from tartaric acid, malic acid, fumaric acid, citric acid and sodium citrate, and preferably, the acid agent is a mixture of malic acid and citric acid, and the mass ratio of the two is 1: (5-6).
When the acid agent is a mixture of malic acid and citric acid, the mass ratio of the two is 1: (5-6), the prepared soybean isoflavone effervescent tablet has good tablet shape, no sticky impact and higher disintegration speed.
In a preferred embodiment of the present invention, the alkaline agent is at least one selected from the group consisting of potassium carbonate, sodium carbonate, calcium carbonate, potassium bicarbonate, sodium bicarbonate and calcium bicarbonate, and preferably, the alkaline agent is sodium bicarbonate.
When the alkaline agent is sodium bicarbonate, the prepared soybean isoflavone effervescent tablet has good tablet shape, no sticky impact and higher disintegration speed.
In a preferred embodiment of the invention, the lubricant is selected from at least one of sodium lauryl sulfate, magnesium stearate, talc, silicon dioxide; preferably, the lubricant is magnesium stearate.
When the lubricant is magnesium stearate, the preparation efficiency is higher, and the dosage form of the prepared tablet is more regular.
According to another aspect of the present invention, the present invention also provides a preparation method of the above soybean isoflavone effervescent tablet, comprising the steps of:
(a) mixing daidzin, daidzein, genistein and genistin to obtain soybean isoflavone composition;
(b) mixing soybean isoflavone composition, vitamin E, vitamin C, acid agent and alkali agent, and mixing with ethanol to obtain soybean isoflavone effervescent granule;
(c) drying the soybean isoflavone effervescent granules, adding a lubricant, uniformly mixing, and tabletting to obtain the soybean isoflavone effervescent tablets.
The preparation method of the soybean isoflavone effervescent tablet provided by the invention has the advantages of simple process, convenience in operation, easiness in large-scale industrial production, reduction in preparation cost and improvement in preparation efficiency.
In a preferred embodiment of the present invention, the method for preparing the effervescent tablet of soybean isoflavone further comprises the step(s) of pulverizing the soybean isoflavone composition, vitamin E, vitamin C, acid agent, alkali agent and lubricant and sieving the pulverized product with a 80-mesh sieve, which is disposed before the steps (a) and (b).
The soybean isoflavone composition, the vitamin E, the vitamin C, the acid agent and the alkali agent are crushed and sieved by a 80-mesh sieve, so that the soybean isoflavone composition, the vitamin E, the vitamin C, the acid agent and the alkali agent are mixed more uniformly, and the drug effect difference among different tablets of the prepared soybean isoflavone effervescent tablet is reduced.
In a preferred embodiment of the invention, in step (c), the temperature of drying is 60-70 ℃, preferably 65 ℃.
By controlling the drying temperature at 60-70 ℃, the drug effect of each raw material is ensured while the ethanol is evaporated, and the phenomena of caking and the like can be avoided, especially when the drying temperature is 65 ℃, the soybean isoflavone effervescent granule has better drying effect and higher drying effect.
In a preferred embodiment of the present invention, in step (b), the prepared effervescent granule of soybean isoflavone has a particle size of 14-18 mesh, preferably 16 mesh.
By controlling the particle size of the soybean isoflavone effervescent granules in the step (b) to be 14-18 meshes, the mixing is more uniform when the subsequent tabletting process is carried out, and the tabletting process is more convenient to carry out.
In a preferred embodiment of the present invention, the preparation method of the soybean isoflavone effervescent tablet comprises the following steps:
(a) mixing daidzin, daidzein, genistein and genistin to obtain soybean isoflavone composition;
(s) respectively crushing the soybean isoflavone composition, the vitamin E, the vitamin C, the acid agent, the alkali agent and the lubricant, and sieving by a sieve of 80 meshes;
(b) dissolving the sieved soybean isoflavone composition, vitamin E, acid agent and alkali agent in ethanol, fully stirring and mixing for 30 minutes to ensure more full and uniform mixing, then granulating to prepare soybean isoflavone effervescent granules, and sieving the soybean isoflavone effervescent granules with a 16-mesh sieve for later use;
(c) drying the sieved soybean isoflavone effervescent granules at 65 ℃, grading, sieving by a 18-mesh sieve, adding a lubricant, uniformly mixing, and tabletting to obtain the soybean isoflavone effervescent tablets.
In order to facilitate understanding of the technical solutions provided by the present invention, the technical solutions provided by the present invention are further described below with reference to the embodiments.
Example 1
The embodiment provides a soybean isoflavone effervescent tablet which is prepared from the following raw materials in parts by mass: 45 parts of soybean isoflavone composition, 3 parts of vitamin E, 55 parts of vitamin C, 835 parts of citric acid, 155 parts of malic acid, 657 parts of sodium bicarbonate and 20 parts of magnesium stearate, wherein the soybean isoflavone composition is a mixture of daidzin, daidzein, genistein and genistin, and the mass ratio of the four is 4:11:6: 2.
Example 2
The embodiment provides a soybean isoflavone effervescent tablet which is prepared from the following raw materials in parts by mass: 55 parts of soybean isoflavone composition, 7 parts of vitamin E, 45 parts of vitamin C, 780 parts of citric acid, 135 parts of malic acid, 657 parts of sodium bicarbonate and 20 parts of magnesium stearate, wherein the soybean isoflavone composition is a mixture of daidzin, daidzein, genistein and genistin, and the mass ratio of the four is 6:9:4: 2.
Example 3
The embodiment provides a soybean isoflavone effervescent tablet which is prepared from the following raw materials in parts by mass: 48 parts of soybean isoflavone composition, 4 parts of vitamin E, 52 parts of vitamin C, 805 parts of citric acid, 155 parts of malic acid, 668 parts of sodium bicarbonate and 18 parts of magnesium stearate, wherein the soybean isoflavone composition is a mixture of daidzin, daidzein, genistein and genistin, and the mass ratio of the four is 5:10:5: 3.
Example 4
The embodiment provides a soybean isoflavone effervescent tablet which is prepared from the following raw materials in parts by mass: the soybean isoflavone composition comprises 52 parts of soybean isoflavone composition, 6 parts of vitamin E, 48 parts of vitamin C, 798 parts of citric acid, 150 parts of malic acid, 680 parts of sodium bicarbonate and 16 parts of magnesium stearate, wherein the soybean isoflavone composition is a mixture of daidzin, daidzein, genistein and genistin, and the mass ratio of the four is 5:10:5: 3.
Example 5
The embodiment provides a soybean isoflavone effervescent tablet which is prepared from the following raw materials in parts by mass: 50 parts of soybean isoflavone composition, 5 parts of vitamin E, 50 parts of vitamin C, 810 parts of citric acid, 150 parts of malic acid, 667.5 parts of sodium bicarbonate and 17.5 parts of magnesium stearate, wherein the soybean isoflavone composition is a mixture of daidzin, daidzein, genistein and genistin, and the mass ratio of the four is 5:10:5: 3.
The preparation method of the soybean isoflavone effervescent tablets provided in examples 1 to 5 is carried out according to the following steps:
(a) mixing daidzin, daidzein, genistein and genistin to obtain soybean isoflavone composition;
(s) respectively crushing the soybean isoflavone composition, the vitamin E, the vitamin C, the acid agent, the alkali agent and the lubricant, and sieving by a sieve of 80 meshes;
(b) dissolving the sieved soybean isoflavone composition, vitamin E, acid agent and alkali agent in ethanol, fully stirring and mixing for 30 minutes to ensure more full and uniform mixing, then granulating to prepare soybean isoflavone effervescent granules, and sieving the soybean isoflavone effervescent granules with a 16-mesh sieve for later use;
(c) drying the sieved soybean isoflavone effervescent granules at 65 ℃, grading, sieving by a 18-mesh sieve, adding a lubricant, uniformly mixing, and tabletting to obtain the soybean isoflavone effervescent tablets.
Comparative example 1
The comparative example provides a soybean isoflavone effervescent tablet which is prepared from the following raw materials in parts by weight: 68 parts of soybean isoflavone composition, 2 parts of vitamin E, 35 parts of vitamin C, 810 parts of citric acid, 150 parts of malic acid, 660 parts of sodium bicarbonate and 25 parts of magnesium stearate, wherein the soybean isoflavone composition is a mixture of daidzin, daidzein, genistein and genistin, and the mass ratio of the four is 5:10:5: 3.
Comparative example 2
The comparative example provides a soybean isoflavone effervescent tablet which is prepared from the following raw materials in parts by weight: 35 parts of soybean isoflavone composition, 10 parts of vitamin E, 75 parts of vitamin C, 800 parts of citric acid, 150 parts of malic acid, 670 parts of sodium bicarbonate and 10 parts of magnesium stearate, wherein the soybean isoflavone composition is a mixture of daidzin, daidzein, genistein and genistin, and the mass ratio of the four is 5:10:5: 3.
Comparative example 3
This comparative example provides a soy isoflavone effervescent tablet which differs from example 5 in that no daidzin is added to the soy isoflavone composition.
Comparative example 4
This comparative example provides a soy isoflavone effervescent tablet, which is different from example 5 in that daidzein was not added to the soy isoflavone composition.
Comparative example 5
This comparative example provides a soy isoflavone effervescent tablet, which is different from example 5 in that genistein was not added to the soy isoflavone composition.
Comparative example 6
This comparative example provides a soy isoflavone effervescent tablet which differs from example 5 in that genistin is not added to the soy isoflavone composition.
Comparative example 7
The comparative example provides a soy isoflavone effervescent tablet, which is different from example 5 in that the soy isoflavone composition is a mixture of daidzin, daidzein, genistein and genistin, and the mass ratio of the four is 1:50:4: 1.
The preparation method of the soybean isoflavone effervescent tablets provided in comparative examples 1 to 7 is the same as that of example 5, and is not repeated herein.
The soybean isoflavone effervescent tablets provided in the above examples 1 to 5 and comparative examples 1 to 7 were tested for their correlation properties, and the test results are shown in the following table:
TABLE 1 table for testing soybean isoflavone effervescent tablet properties
As can be seen from Table 1, the soybean isoflavone effervescent tablets provided in examples 1 to 5 of the present invention have a good tablet shape, no sticky punch, clear and transparent solution after dissolution, pH of 4.1 to 4.3, rapid disintegration, disintegration time of 81 to 85s, substantially unchanged weight and taste within 3 months, and good stability.
As can be seen from the comparison of examples 1-5 with comparative examples 1-2, when the soy isoflavone composition, vitamin E, vitamin C, acid agent, alkali agent and sodium citrate are in a specific mass portion range, the raw materials are synergistically matched, and the obtained soy isoflavone effervescent tablet has a good tablet shape, is free from sticky flushing and is more reliable for drinkers.
In addition, the isoflavone effervescent tablets provided in examples 1 to 5 and comparative examples 1 to 7 were each subjected to a microbial test in months 1, 2 and 3, respectively, and no microbial presence was found.
To verify that the soybean isoflavone effervescent tablets provided in examples 1 to 5 and comparative examples 1 to 7 were subjected to clinical trials, 1300 women of 40 to 50 years old were randomly drawn and divided into 13 groups of 100 persons each, and each of the groups was a group a to M, wherein the group a to E were administered with the soybean isoflavone effervescent tablets provided in examples 1 to 5, the group F to L were administered with the soybean isoflavone effervescent tablets provided in comparative examples 1 to 7, the group P was a blank control group, the group a to L were administered with 3.5g of soybean isoflavone effervescent tablets per day, and the group M was not administered with the soybean isoflavone effervescent tablets, and the results were counted after 6 months, as shown in the following table:
TABLE 2 clinical examination table for soybean isoflavone effervescent tablets
The comparison between the groups A-E and the group M shows that after the group A-E women take the soybean isoflavone for 6 months, the proportion of the climacteric discomfort people and the proportion of the menstrual discomfort people is obviously reduced, which shows that the soybean isoflavone provided by the embodiments 1-5 of the invention can supplement estrogen for the women, effectively relieve the climacteric and menstrual discomfort symptoms and improve the immunity of the organism.
The comparison between the groups A-E and F-G shows that when the soybean isoflavone composition, the vitamin E, the vitamin C, the acid agent, the alkali agent and the sodium citrate are in a specific mass part range, all the raw materials are cooperated with one another, so that the discomfort of the female in menopause and menstrual period can be obviously reduced, and the immunity of the female organism can be improved; comparing the groups A-E with the groups H-L, the soybean isoflavone composition is a mixture of daidzin, daidzein, genistein and genistin, and the mass ratio of the four is (3-4): (18-20): (3-4): (1-2), the soybean isoflavone effervescent tablet prepared by the method has better effect on relieving female menstrual discomfort and climacteric discomfort symptoms.
In addition, by tracking the daily work and rest conditions of the 13 groups of people, the A-E group women have higher sleep quality, fewer sicknesses, stronger immunity, redder complexion and more vigorous energy.
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.
Claims (7)
1. A soybean isoflavone effervescent tablet is characterized in that,
the composite material is prepared from the following raw materials in parts by weight: 48-52 parts of soybean isoflavone composition, 4-6 parts of vitamin E, 48-52 parts of vitamin C, 980 parts of acid agent 940-;
the acid agent is a mixture of malic acid and citric acid, and the mass ratio of the malic acid to the citric acid is 1: (5-6);
the alkaline agent is sodium bicarbonate;
the lubricant is magnesium stearate.
2. The method for preparing soybean isoflavone effervescent tablets of claim 1, which comprises the following steps:
(a) mixing daidzin, daidzein, genistein and genistin uniformly to obtain soybean isoflavone composition;
(b) mixing soybean isoflavone composition, vitamin E, vitamin C, acid agent and alkali agent, and mixing with ethanol to obtain soybean isoflavone effervescent granule;
(c) drying the soybean isoflavone effervescent granules, adding a lubricant, uniformly mixing, and tabletting to obtain the soybean isoflavone effervescent tablets.
3. The method for preparing soybean isoflavone effervescent tablets of claim 2, further comprising a step(s) of pulverizing the soybean isoflavone composition, vitamin E, vitamin C, acid agent, alkali agent and lubricant and sieving the pulverized product with a 80-mesh sieve, wherein the step(s) is performed before the step (a) and the step (b).
4. The method for preparing effervescent tablet of soybean isoflavone as claimed in claim 2, wherein the drying temperature in step (c) is 60-70 ℃.
5. The method for preparing effervescent tablet of soybean isoflavone as claimed in claim 4, wherein the drying temperature in step (c) is 65 ℃.
6. The method for preparing soybean isoflavone effervescent tablets according to claim 2, wherein the soybean isoflavone effervescent granules prepared in the step (b) have a particle size of 14 to 18 meshes.
7. The method for preparing soybean isoflavone effervescent tablets according to claim 6, wherein the prepared soybean isoflavone effervescent granules have a particle size of 16 meshes in the step (b).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710589036.1A CN107373272B (en) | 2017-07-19 | 2017-07-19 | Soybean isoflavone effervescent tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710589036.1A CN107373272B (en) | 2017-07-19 | 2017-07-19 | Soybean isoflavone effervescent tablet and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107373272A CN107373272A (en) | 2017-11-24 |
| CN107373272B true CN107373272B (en) | 2020-11-06 |
Family
ID=60339283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710589036.1A Active CN107373272B (en) | 2017-07-19 | 2017-07-19 | Soybean isoflavone effervescent tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107373272B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1589786A (en) * | 2003-09-01 | 2005-03-09 | 郑州博凯医药保健品有限公司 | Composite effervescent preparation containing soya isoflavone |
| CN103110687A (en) * | 2011-11-17 | 2013-05-22 | 胡晓娟 | Compound effervescent preparation containing soy isoflavone |
-
2017
- 2017-07-19 CN CN201710589036.1A patent/CN107373272B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1589786A (en) * | 2003-09-01 | 2005-03-09 | 郑州博凯医药保健品有限公司 | Composite effervescent preparation containing soya isoflavone |
| CN103110687A (en) * | 2011-11-17 | 2013-05-22 | 胡晓娟 | Compound effervescent preparation containing soy isoflavone |
Non-Patent Citations (2)
| Title |
|---|
| 博凯维康 康伊丽大豆异黄酮维生素C维生素E泡腾片1.75g/片*20片;博凯维康品牌专卖店;《非彤小可商城》;20150803;第1-8页 * |
| 博凯维康品牌专卖店.博凯维康 康伊丽大豆异黄酮维生素C维生素E泡腾片1.75g/片*20片.《非彤小可商城》.2015, * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107373272A (en) | 2017-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1956734B (en) | Multi-vitamin and mineral nutritional supplements | |
| CN107929313B (en) | Natural oyster calcium carbonate preparation for preventing and treating calcium deficiency and preparation method thereof | |
| CN105567771A (en) | Pigskin small peptide chelate and preparation method and application thereof | |
| CN107232611A (en) | A kind of nutrient composition being made up of vitamin D, K and folic acid | |
| CN1327838C (en) | Vitamin C oral disintegration tablet and its preparing method | |
| CN104664370A (en) | Chewable flax tablet | |
| CN106418545A (en) | Functional food with balanced nutrients | |
| CN102742658B (en) | Goat milk tablet for maintaining beauty and keeping young and preparation method of goat milk tablet | |
| CN103735556A (en) | Multivitamin mineral composite effervescent tablet and preparation method thereof | |
| KR20140017977A (en) | Vita hybrid tablet for senior and manufacturing method thereof | |
| CN107373272B (en) | Soybean isoflavone effervescent tablet and preparation method thereof | |
| KR20080090808A (en) | Composition of healthy food for a skin | |
| CN107373273B (en) | Adult type multivitamin mineral effervescent tablet and preparation method thereof | |
| CN106901378A (en) | A kind of health food suitable for women | |
| CN112370430A (en) | Calcium and vitamin K2 tablet and preparation method thereof | |
| WO2013074046A1 (en) | Pharmaceutical formulations comprising isoflavone | |
| JP2004315455A (en) | Agent for ameliorating or treating backache, pelvic pain or pain derived from varicosis in pregnancy or leg cramp | |
| CN101366777B (en) | Medicament composition for preventing birth defection and improving memory | |
| CN101274006B (en) | Pharmaceutical combination of prepotency for preventing birth-defect and improving memory | |
| CN106912929A (en) | A kind of health food nutritional agents and preparation method with anti-fatigue effect | |
| CN113952447A (en) | Multi-taste calcium chewable tablet and production and manufacturing process thereof | |
| UA148151U (en) | METHOD OF PREPARATION OF PREPARATIVE PHARMACEUTICAL FORM FOR ORAL USE FOR DELIVERY OF DAILY DOSE OF VITAMIN C | |
| CN112137113A (en) | Formula of vitamin E tablets and preparation method thereof | |
| CN109418809A (en) | A kind of prune chewable tablets and preparation method thereof | |
| CN101274002B (en) | Pharmaceutical combination of prepotency for preventing birth-defect and improving memory |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: No.1302, No.7, Dongqing street, high tech Industrial Development Zone, Zhengzhou City, Henan Province 450001 Applicant after: Bokai Pharmaceutical Co., Ltd Address before: 450000 No. 5 Acacia Street, hi tech Development Zone, Henan, Zhengzhou Applicant before: Zhengzhou Bokai Medicine &. Health-Care Products Co., Ltd. |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |